论文部分内容阅读
目的:分析早期2型糖尿病肾病蛋白尿实施药物联合治疗的方法和效果。方法:以我院2014年1月至2015年12月收治的56例患者作为研究对象,随机分为两个组别,对照组(前列地尔治疗)、试验组(前列地尔+依帕司他治疗)各28例,观察比较临床疗效和不良反应情况。结果:治疗前后试验组UAE、ALB、BUN、Scr指标差异明显,且治疗后的各项指标优于对照组;治疗后试验组FBG、TC、TG为(6.1±0.7)、(5.4±0.3)、(1.6±0.6)mmol/L,低于对照组的(6.4±0.8)、(6.0±0.5)、(2.1±0.8)mmol/L。P<0.05,差异有统计学意义。结论:针对早期2型糖尿病肾病蛋白尿,前列地尔联合依帕司他的治疗效果更佳,有利于保护患者的肾功能,值得推广。
OBJECTIVE: To analyze the methods and effects of drug combination therapy in type 2 diabetic nephropathy. Methods: Fifty-six patients admitted to our hospital from January 2014 to December 2015 were randomly divided into two groups: control group (alprostadil), test group (alprostadil + He treated) 28 cases each, observed and compared the clinical efficacy and adverse reactions. Results: Before and after treatment, the indexes of UAE, ALB, BUN and Scr in the experimental group were significantly different, and the indexes after treatment were better than those in the control group. After treatment, the FBG, TC and TG in the experimental group were (6.1 ± 0.7) and (5.4 ± 0.3) , (1.6 ± 0.6) mmol / L lower than the control group (6.4 ± 0.8), (6.0 ± 0.5) and (2.1 ± 0.8) mmol / L respectively. P <0.05, the difference was statistically significant. Conclusion: In the early stage of type 2 diabetic nephropathy proteinuria, the combination of alprostadil and alprostadil is more effective in protecting renal function of patients and is worth promoting.